Factors influencing the inhibition of protein kinases

The protein kinase field is a very active research area in the pharmaceutical industry and many activities are ongoing to identify inhibitors of these proteins. The design of new chemical entities with improved pharmacological properties requires a deeper understanding of the factors that modulate inhibitor–kinase interactions. In this report, we studied the effect of two of these factors—the magnesium ion cofactor and the protein substrate—on inhibitors of the type I insulin-like growth factor receptor. Our results show that the concentration of magnesium ion influences the potency of adenosine triphosphate (ATP) competitive inhibitors, suggesting an explanation for the observation that such compounds retain their nanomolar potency in cells despite the presence of millimolar levels of ATP. We also showed that the peptidic substrate affects the potency of these inhibitors in a different manner, suggesting that the influence of this substrate on compound potency should be taken into consideration during drug discovery.

[1]  D. Erdmann,et al.  Study of the Selectivity of Insulin-Like Growth Factor-1 Receptor (IGF1R) Inhibitors , 2014 .

[2]  D. Erdmann,et al.  Simultaneous protein expression and modification: an efficient approach for production of unphosphorylated and biotinylated receptor tyrosine kinases by triple infection in the baculovirus expression system. , 2010, Journal of biomolecular techniques : JBT.

[3]  D. Swinney,et al.  Steady-state kinetic characterization of kinase activity and requirements for Mg2+ of interleukin-1 receptor-associated kinase-4. , 2010, Biochemistry.

[4]  Y. Yagi,et al.  Kinetic mechanism and inhibitor characterization of WNK1 kinase. , 2009, Biochemistry.

[5]  G. Alton,et al.  Characterization of the CHK1 allosteric inhibitor binding site. , 2009, Biochemistry.

[6]  Rongshi Li,et al.  Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach. , 2009, Journal of medicinal chemistry.

[7]  R. Kriz,et al.  Activation loop phosphorylation modulates Bruton's tyrosine kinase (Btk) kinase domain activity. , 2009, Biochemistry.

[8]  Robert A. Copeland,et al.  Defining Balanced Conditions for Inhibitor Screening Assays That Target Bisubstrate Enzymes , 2009, Journal of biomolecular screening.

[9]  R. Abagyan,et al.  Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states. , 2008, Journal of medicinal chemistry.

[10]  S. Hubbard,et al.  Small‐molecule inhibition and activation‐loop trans‐phosphorylation of the IGF1 receptor , 2008, The EMBO journal.

[11]  M. Glicksman,et al.  Kinetic studies of Cdk5/p25 kinase: phosphorylation of tau and complex inhibition by two prototype inhibitors. , 2008, Biochemistry.

[12]  P. Chène.  Challenges in design of biochemical assays for the identification of small molecules to target multiple conformations of protein kinases. , 2008, Drug discovery today.

[13]  R. Thaimattam,et al.  Protein kinase inhibitors: structural insights into selectivity. , 2007, Current pharmaceutical design.

[14]  D. Fairlie,et al.  A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. , 2007, Drug discovery today.

[15]  N. Gibson,et al.  A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor–dependent tumor growth in vivo , 2007, Molecular Cancer Therapeutics.

[16]  Jeffrey Jie-Lou Liao,et al.  Molecular Recognition of Protein Kinase Binding Pockets for Design of Potent and Selective Kinase Inhibitors , 2007 .

[17]  B. Shoichet.  Screening in a spirit haunted world. , 2006, Drug discovery today.

[18]  N. Gray,et al.  Rational design of inhibitors that bind to inactive kinase conformations , 2006, Nature chemical biology.

[19]  S. Stirdivant,et al.  Biochemical and structural characterization of a novel class of inhibitors of the type 1 insulin-like growth factor and insulin receptor kinases. , 2005, Biochemistry.

[20]  W. Miller,et al.  Inhibition of insulin-like growth factor I receptor autophosphorylation by novel 6-5 ring-fused compounds. , 2004, Biochemical pharmacology.

[21]  M. Malkowski,et al.  Screening for small molecule inhibitors of insulin-like growth factor receptor (IGF-1R) kinase: comparison of homogeneous time-resolved fluorescence and 33P-ATP plate assay formats. , 2004, Journal of experimental therapeutics and oncology.

[22]  D. Fabbro,et al.  In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. , 2004, Cancer cell.

[23]  Stevan R. Hubbard,et al.  Structure and autoregulation of the insulin-like growth factor 1 receptor kinase , 2001, Nature Structural Biology.

[24]  J. Adams,et al.  Kinetic and catalytic mechanisms of protein kinases. , 2001, Chemical reviews.

[25]  F. Ashcroft,et al.  A Novel Method for Measurement of Submembrane ATP Concentration* , 2000, The Journal of Biological Chemistry.

[26]  H. Kennedy,et al.  Glucose generates sub-plasma membrane ATP microdomains in single islet beta-cells. Potential role for strategically located mitochondria. , 1999, The Journal of biological chemistry.

[27]  J. Adams,et al.  A second magnesium ion is critical for ATP binding in the kinase domain of the oncoprotein v-Fps. , 1998, Biochemistry.

[28]  L Tao,et al.  Turnover of the Acyl Phosphates of Human and Murine Prothymosin α in Vivo * , 1997, The Journal of Biological Chemistry.

[29]  S. Taylor,et al.  Divalent metal ions influence catalysis and active‐site accessibility in the camp‐dependent protein kinase , 1993, Protein science : a publication of the Protein Society.

[30]  M. Macdermott.  The intracellular concentration of free magnesium in extensor digitorum longus muscles of the rat , 1990, Experimental physiology.

[31]  K. Vrana,et al.  Adenosine cyclic 3',5'-monophosphate dependent protein kinase: kinetic mechanism for the bovine skeletal muscle catalytic subunit. , 1982, Biochemistry.

[32]  E. Brown,et al.  Divalent cation metabolism. Familial hypocalciuric hypercalcemia versus typical primary hyperparathyroidism. , 1978, The American journal of medicine.

[33]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[34]  Robert A. Copeland,et al.  Evaluation of enzyme inhibitors in drug discovery , 2013 .

[35]  N. Gray,et al.  Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.

[36]  R. Kumar,et al.  Divalent Cation Metabolism : Magnesium , 2000 .